Business
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity
VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and in
About this update from Avita Medical, Inc.
[{"type":"image","alt":"AVITA Medical","displaySize":"","headline":null,"caption":"AVITA Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":96,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejDr4RdwXqFCjMdbUOz.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115}},"lazy":false},{"type":"text","content":"VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and initial clinical utilization, an integrated wound bed was seen as early as 7 days.","length":580,"tagName":"p"},{"type":"text","content":"Cohealyx expands AVITA Medical’s therapeutic wound care portfolio, complementing its flagship product, the RECELL® System, which is FDA-approved for the treatment of thermal burns and full-thickness skin defects, and PermeaDerm®, a temporary biosynthetic dressing used to support healing before and after grafting. These products support the two-stage standard of care for full-thickness wounds. Cohealyx is used as a dermal matrix to manage the wound bed. RECELL Spray-On Skin™ Cells and wound protection with PermeaDerm provide solutions for definitive closure. This integrated approach may improve clinical outcomes and expands AVITA Medical’s market opportunity.","length":671,"tagName":"p"},{"type":"text","content":"“When treating full-thickness acute wounds in a two-stage procedure, a shorter time to graft readiness translates to a shorter hospital stay for the patient,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “During our pre-clinical validated porcine model study, wounds treated with Cohealyx were consistently graft-ready faster than the leading competitors used as controls. This treatment regimen has the potential to deliver faster healing and shorter hospital stays, consiste...